PRGO Quote, Financials, Valuation and Earnings

Amarin Corp PLC has a net margin of -3.91% compared to Perrigo Co PLC's net margin of -78.03%. Perrigo Co PLC's return on equity of -3.76% beat Amarin Corp PLC's return on equity of -15.41%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 37.63%. On the other hand Amarin Corp PLC has an analysts' consensus of $13.50 which suggests that it could grow by 44.23%. Given that Amarin Corp PLC has higher upside potential than Perrigo Co PLC, analysts believe Amarin Corp PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.487, which suggesting that the stock is 51.326% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 1.384, suggesting its more volatile than the S&P 500 by 38.378%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.45%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Amarin Corp PLC quarterly revenues of $62.3M. Perrigo Co PLC's net income of -$44.5M is higher than Amarin Corp PLC's net income of -$48.6M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.79x versus 0.84x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.

Avadel Pharmaceuticals PLC has a net margin of -3.91% compared to Perrigo Co PLC's net margin of -10%. Perrigo Co PLC's return on equity of -3.76% beat Avadel Pharmaceuticals PLC's return on equity of -63.43%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 37.63%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.70 which suggests that it could grow by 117.18%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.487, which suggesting that the stock is 51.326% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.847%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.45%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $50.4M. Perrigo Co PLC's net income of -$44.5M is lower than Avadel Pharmaceuticals PLC's net income of -$5M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.79x versus 4.58x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -3.91% compared to Perrigo Co PLC's net margin of 17.56%. Perrigo Co PLC's return on equity of -3.76% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 37.63%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $192.22 which suggests that it could grow by 89.29%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.487, which suggesting that the stock is 51.326% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.096%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.45%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Perrigo Co PLC's net income of -$44.5M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 11.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.79x versus 1.60x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of -3.91% compared to Perrigo Co PLC's net margin of 15.61%. Perrigo Co PLC's return on equity of -3.76% beat Medtronic PLC's return on equity of 8.56%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 37.63%. On the other hand Medtronic PLC has an analysts' consensus of $96.83 which suggests that it could grow by 17.09%. Given that Perrigo Co PLC has higher upside potential than Medtronic PLC, analysts believe Perrigo Co PLC is more attractive than Medtronic PLC.

Perrigo Co PLC has a beta of 0.487, which suggesting that the stock is 51.326% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.554%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.45%. Medtronic PLC offers a yield of 3.39% to investors and pays a quarterly dividend of $0.70 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co PLC quarterly revenues are $1.1B, which are smaller than Medtronic PLC quarterly revenues of $8.3B. Perrigo Co PLC's net income of -$44.5M is lower than Medtronic PLC's net income of $1.3B. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 25.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.79x versus 3.23x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.